AAAAAA

   
Results: 1-13 |
Results: 13
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial
Authors: Adenis, A Bonneterre, J Bonneterre, ME Pion, JM Vanlemmens, L Gladieff, L de Lafontan, B Martel, P Mihura, J Roche, H Gedouin, D Kerbrat, P Lesimple, T Bremond, A Devaux, Y Delecroix, V Fumoleau, P Maugard-Louboutin, C Namer, M Goudier, MJ Morice, F Montcuquet, P Schraub, S Coudert, B Fargeot, P de Gislain, C Mayer, F Bastit, P Chevallier, B Grandgirard, A Monnier, A Sun, X Clavere, P Ollivier, JP Rhein, B Roullet, B Datchary, J Audhuy, B Barats, JC Kohser, F Dides, S Ramos, R Cattan, A Eymard, JC Pourny, C Weber, B de Laroche, G Pichon, A Seffert, P Hayat, M Zambon, E Chollet, P Van Praagh, I
Citation: A. Adenis et al., Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial, J CL ONCOL, 19(3), 2001, pp. 602-611
Biodistribution of (111)indium-labeled macrophages infused intravenously in patients with renal carcinoma
Authors: Quillien, V Moisan, A Lesimple, T Leberre, C Toujas, L
Citation: V. Quillien et al., Biodistribution of (111)indium-labeled macrophages infused intravenously in patients with renal carcinoma, CANCER IMMU, 50(9), 2001, pp. 477-482
Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor
Authors: Lesimple, T Moisan, A Guille, F Leberre, C Audran, R Drenou, B Toujas, L
Citation: T. Lesimple et al., Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor, J IMMUNOTH, 23(6), 2000, pp. 675-679
Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer
Authors: Bouet-Toussaint, F Genetet, N Rioux-Leclercq, N Bansard, JY Leveque, J Guille, F Patard, JJ Lesimple, T Catros-Quemener, V
Citation: F. Bouet-toussaint et al., Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer, EUR CYTOKIN, 11(2), 2000, pp. 217-224
Infection and cancer: background and current issues
Authors: Viot, M Blanc-Vincent, MP Beal, J Biron, P Boutard, P Malgrange, VB Crokaert, F Escande, MC Fuhrmann, C Lesimple, T Peny, J Pottecher, B Raveneau, J Senet, JM Thyss, A
Citation: M. Viot et al., Infection and cancer: background and current issues, PRESSE MED, 29(29), 2000, pp. 1630-1633
Standards, options and guidelines for good clinical use of blood cultures in oncology
Authors: Malgrange, VB Blanc-Vincent, MP Escande, MC Fuhrmann, C Beal, J Boineau, F Biron, P Crokaert, F Lesimple, T Pottecher, B Raveneau, J Senet, JM Viot, M
Citation: Vb. Malgrange et al., Standards, options and guidelines for good clinical use of blood cultures in oncology, PRESSE MED, 29(27), 2000, pp. 1532-1534
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
Authors: Negrier, S Caty, A Lesimple, T Douillard, JY Escudier, B Rossi, JF Viens, P Gomez, F
Citation: S. Negrier et al., Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil, J CL ONCOL, 18(24), 2000, pp. 4009-4015
Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment
Authors: Bastit, P Chevallier, B Chevreau, C Mihura, J Roche, H Namer, M Gedouin, D Kerbrat, P Lesimple, T Coudert, B Fargeot, P de Gislain, C Mayer, F Luporsi, E Rios, M Weber, B Bremond, A Devaux, Y Monteuquet, P Schraub, S Hayat, M Zambon, E Grandgirard, A Monnier, A Sun, X Clavere, P Ollivier, JP Rhein, B Roullet, B Chollet, P Van Praagh, I Cattan, A Eymard, JC Pourny, C Facchini, T Walter, S Dides, S Ramos, R Guiochet, N Seffert, P Perpoint, X Sztermer, JF Cretin, J Goudier, MJ Morice, F Delecroix, V Fumoleau, P
Citation: P. Bastit et al., Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment, J CL ONCOL, 18(17), 2000, pp. 3115-3124
Serum S100B protein and cutaneous malignant melanoma stage: a prospective study.
Authors: Brouard, M Quillien, V Ollivier, I Lesimple, T Adamski, H Chevrant-Breton, J
Citation: M. Brouard et al., Serum S100B protein and cutaneous malignant melanoma stage: a prospective study., ANN DER VEN, 127(1), 2000, pp. 56-59
Standards, Options and Recommendations (SOR) for the surveillance and the prevention of cross infections in oncology (vol 87, pg 557, 2000)
Authors: Pottecher, B Herbrecht, R BlancVincent, MP Malgrange, VB Escande, MC Fuhrmann, C Crokaert, F GoryDelabaere, G Senet, JM Lesimple, T Raveneau, J Beal, J Biron, P Viot, M
Citation: B. Pottecher et al., Standards, Options and Recommendations (SOR) for the surveillance and the prevention of cross infections in oncology (vol 87, pg 557, 2000), B CANCER, 87(9), 2000, pp. 630-630
Standards, Options and Recommendations (SOR) for the surveillance and the prevention of cross infections in oncology
Authors: Pottecher, B Herbrecht, R Blanc-Vincent, MP Malgrange, VB Escande, MC Fuhrmann, C Crokaert, F Gory-Delabaere, G Senet, JM Lesimple, T Raveneau, J Beal, J Biron, P Viot, M
Citation: B. Pottecher et al., Standards, Options and Recommendations (SOR) for the surveillance and the prevention of cross infections in oncology, B CANCER, 87(7-8), 2000, pp. 557-591
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation study
Authors: Lhomme, C Vennin, P Callet, N Lesimple, T Achard, JL Chauvergne, J Luporsi, E Chinet-Charrot, P Coudert, B Couette, JE Guastalla, JP Lebrun, D Ispas, S Blumberg, J
Citation: C. Lhomme et al., A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation study, GYNECOL ONC, 75(2), 1999, pp. 187-193
Toxicity and feasibility of adjuvant high dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
Authors: Ravaud, A Bedane, C Geoffrois, L Lesimple, T Delaunay, M
Citation: A. Ravaud et al., Toxicity and feasibility of adjuvant high dose interferon alpha-2b in patients with melanoma in clinical oncologic practice, BR J CANC, 80(11), 1999, pp. 1767-1769
Risultati: 1-13 |